Cantor Fitzgerald Maintains Overweight on Surrozen, Raises Price Target to $62
Surrozen, Inc. SRZN
$33.05
▲ +3.28%
(+$1.05)
🔥 High Short Interest
🎈 Low Float
Open
$32.57
Prev Close
$32.00
Day Range
$31.23 – $33.51
52W Range
$11.51 – $37.83
Market Cap
$376.11M
Beta
0.63
EPS (TTM)
$-35.79
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-11-23 |
| Shares Out. | 17,800,000 |
| Website | surrozen.com ↗ |
| Phone | 13026587581 |
| Employees | 44 |
| Revenue | $5.0M |
| Gross Profit | $5.0M |
| Net Income | $50.2M |
| Free Cash Flow | -$35.0M |
| Total Assets | $115.6M |
| Total Liabilities | $334.3M |
| Equity | -$218.7M |
About Surrozen, Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).
Surrozen, Inc. is a publicly traded company under the ticker symbol SRZN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-11-01)